+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid therapy in patients with primary biliary cirrhosis



Ursodeoxycholic acid therapy in patients with primary biliary cirrhosis



Hepatology 14(4 Part 2): 91A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144912

Download citation: RISBibTeXText


Related references

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterologie Clinique et Biologique 34(4-5): 283-287, 2010

Ursodeoxycholic acid is beneficial therapy for patients with primary biliary cirrhosis. Hepatology 16(4 Part 2): 91A, 1992

Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Journal Of Hepatology. 18(3): 373-377, 1993

Response to ursodeoxycholic acid therapy is predictable in patients with primary biliary cirrhosis. Gastroenterology 114(4 Part 2): A1288, April 15, 1998

Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid. Digestive Diseases 33(Suppl. 2): 125-133, 2016

Pretransplant ursodeoxycholic acid therapy and liver transplantation in patients with primary biliary cirrhosis: win, win, win?. Liver Transplantation and Surgery 5(4): 334-337, 1999

Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. Journal of Hepatology 18(1): 9-14, 1993

The effects of colchicine and methotrexate are additive to ursodeoxycholic acid for patients with primary biliary cirrhosis who respond incompletely to ursodeoxycholic acid. Hepatology 26(4 Part 2): 438A, 1997

Ursodeoxycholic acid therapy plays an immunomodulatory and anti-apoptotic role in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Journal of Hepatology 38(Suppl. 2): 208, 2003

Effects of hepatocellular carcinoma on the survival of patients with primary biliary cirrhosis in the era of ursodeoxycholic acid therapy. Internal Medicine 52(14): 1543-1544, 2014

Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Alimentary Pharmacology & Therapeutics 24(5): 813-820, 2006

Ursodeoxycholic acid therapy affects the cytokine network and plays an immunomodulatory role in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 36(4 Part 2): 499A, 2002

Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transplantation and Surgery 5(4): 269-274, 1999

Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. Journal of Digestive Diseases 13(4): 219-224, 2012

Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 29(1): 39-43, 1999